Tower Research Capital LLC (Trc) Moleculin Biotech, Inc. Transaction History

Tower Research Capital LLC (Trc)

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.41 - $0.86 $2,912 - $6,109	-7,104 Reduced 49.66%	7,201 $6,000
Q3 2023 Nov 14, 2023	SELL	$0.38 - $0.72 $26 - $49	-69 Reduced 0.48%	14,305 $6,000
Q2 2023 Aug 14, 2023	BUY	$0.54 - $0.95 $1,104 - $1,942	2,045 Added 16.59%	14,374 $8,000
Q1 2023 May 09, 2023	BUY	$0.9 - $1.34 $6,276 - $9,345	6,974 Added 130.23%	12,329 $12,000
Q4 2022 Feb 10, 2023	SELL	$0.85 - $16.65 $3,754 - $73,543	-4,417 Reduced 45.2%	5,355 $6,000
Q3 2022 Nov 10, 2022	BUY	$1.15 - $17.4 $6,430 - $97,300	5,592 Added 133.78%	9,772 $10,000
Q2 2022 Aug 15, 2022	SELL	$1.19 - $2.0 $13 - $22	-11 Reduced 0.26%	4,180 $6,000
Q1 2022 May 12, 2022	BUY	$1.23 - $1.9 $5,154 - $7,962	4,191 New	4,191 $7,000
Q4 2021 Feb 14, 2022	SELL	$1.64 - $2.83 $65 - $113	-40 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.7 - $3.59 $6,677 - $8,878	-2,473 Reduced 98.41%	40 $0
Q2 2021 Aug 16, 2021	BUY	$3.21 - $4.06 $8,066 - $10,202	2,513 New	2,513 $9,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $72.7M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.